PReP: Last News


Coming Soon: Long-Lasting, Injectable PrEP

At this year’s 2022 Internationaal AIDS Conference, ViiV Healthcare presented research that cast a spotlight on the efficacy of cabotegravir long-acting (LA) for HIV pre-exposure prophylaxis (PrEP).In a recent article posted by Healthline, this injectable form of PrEP complements other recent pushes for placing HIV prevention efforts higher on the list of urgency. As cabotegravir LA is the first and currently only long-acting injectable form of PrEP, it could change the face of HIV prevention.The trial for cabotegravir LA determined that the injectable form of PrEP resulted in an “89% lower rate of HIV acquisition” as compared to a regimen of oral tablets.Alex Rinehart, PhD, the Medicines Development Leader and HIV Prevention at ViiV Healthcare, noted that both injectable and oral variations of PrEP helped substantially reduce the risk of getting HIV.

Related News